{"id":6419,"date":"2026-06-02T09:01:28","date_gmt":"2026-06-02T09:01:28","guid":{"rendered":"https:\/\/team4bps.com\/?p=6419"},"modified":"2026-06-02T09:02:13","modified_gmt":"2026-06-02T09:02:13","slug":"%d8%a7%d9%84%d8%a8%d9%88%d8%b1%d8%af-%d8%a7%d9%84%d8%a3%d9%85%d8%b1%d9%8a%d9%83%d9%8a-%d9%81%d9%8a-%d8%b5%d9%8a%d8%af%d9%84%d8%a9-%d8%a7%d9%84%d8%a3%d9%88%d8%b1%d8%a7%d9%85-bcop%d8%9f","status":"publish","type":"post","link":"https:\/\/team4bps.com\/ar\/%d8%a7%d9%84%d8%a8%d9%88%d8%b1%d8%af-%d8%a7%d9%84%d8%a3%d9%85%d8%b1%d9%8a%d9%83%d9%8a-%d9%81%d9%8a-%d8%b5%d9%8a%d8%af%d9%84%d8%a9-%d8%a7%d9%84%d8%a3%d9%88%d8%b1%d8%a7%d9%85-bcop%d8%9f\/","title":{"rendered":"\u0627\u0644\u0628\u0648\u0631\u062f \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a \u0641\u064a \u0635\u064a\u062f\u0644\u0629 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (BCOP)\u061f"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">\u0627\u0644\u0641\u062a\u0631\u0629 \u0627\u0644\u0623\u062e\u064a\u0631\u0629 \u0641\u064a\u0647 <\/span><b>\u062a\u0632\u0627\u064a\u062f \u0643\u0628\u064a\u0631 \u062c\u062f\u0627\u064b<\/b><span style=\"font-weight: 400;\"> \u0641\u064a \u0637\u0644\u0628\u0627\u062a \u062a\u0648\u0638\u064a\u0641 \u0627\u0644\u0635\u064a\u0627\u062f\u0644\u0629 \u0627\u0644\u062d\u0627\u0635\u0644\u064a\u0646 \u0639\u0644\u0649 \u0627\u0644\u0628\u0648\u0631\u062f \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a \u0641\u064a \u062a\u062e\u0635\u0635 \u0627\u0644\u0623\u0648\u0631\u0627\u0645\u061f\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u0627\u0644\u0639\u062f\u062f \u0627\u0644\u0645\u0637\u0644\u0648\u0628 <\/span><b>\u0623\u0643\u0628\u0631 \u0645\u0646 \u0627\u0644\u0645\u062a\u0627\u062d<\/b><span style=\"font-weight: 400;\"> \u2014 \u0633\u0648\u0627\u0621 \u0641\u064a \u0645\u0635\u0631 \u0623\u0648 \u0627\u0644\u0648\u0637\u0646 \u0627\u0644\u0639\u0631\u0628\u064a. \u0644\u0623\u0646 \u0623\u0639\u062f\u0627\u062f \u0627\u0644\u0645\u0633\u062a\u0634\u0641\u064a\u0627\u062a \u0627\u0644\u062d\u0643\u0648\u0645\u064a\u0629 \u0648\u0627\u0644\u0645\u0631\u0627\u0643\u0632 \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0639\u0644\u0627\u062c \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0628\u064a\u0632\u064a\u062f \u0639\u062f\u062f\u0647\u0627 \u0643\u0644 \u0633\u0646\u0629.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u0627\u0644\u062d\u0627\u062c\u0629 \u0627\u0644\u0645\u0644\u062d\u0629 \u062f\u0644\u0648\u0642\u062a\u064a <\/span><b>\u0635\u064a\u062f\u0644\u064a \u0625\u0643\u0644\u064a\u0646\u064a\u0643\u064a \u0645\u062a\u062e\u0635\u0635<\/b><span style=\"font-weight: 400;\"> \u0642\u0627\u062f\u0631 \u0639\u0644\u0649:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">\u062a\u0642\u064a\u064a\u0645 \u0627\u0644\u062d\u0627\u0644\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u0645\u0631\u064a\u0636<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">\u062d\u0633\u0627\u0628 \u0627\u0644\u062c\u0631\u0639\u0627\u062a \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (<\/span><b>Chemotherapy Dosing<\/b><span style=\"font-weight: 400;\">)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">\u0645\u062a\u0627\u0628\u0639\u0629 <\/span><b>\u0627\u0644\u062a\u0641\u0627\u0639\u0644\u0627\u062a \u0627\u0644\u062f\u0648\u0627\u0626\u064a\u0629<\/b><span style=\"font-weight: 400;\"> (Drug Interactions)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">\u0645\u0631\u0627\u0642\u0628\u0629 <\/span><b>\u0627\u0644\u062a\u0623\u062b\u064a\u0631\u0627\u062a \u0627\u0644\u062d\u064a\u0648\u064a\u0629<\/b><span style=\"font-weight: 400;\"> \u0639\u0644\u0649 \u062c\u0645\u064a\u0639 \u0623\u0639\u0636\u0627\u0621 \u0627\u0644\u062c\u0633\u0645 (Organ Toxicity)<\/span><\/li>\n<\/ul>\n<h2><b>\u0625\u064a\u0647 \u0647\u0648 \u0627\u0644\u0628\u0648\u0631\u062f \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a \u0641\u064a \u0635\u064a\u062f\u0644\u0629 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (BCOP)\u061f<\/b><\/h2>\n<p><b>Board-Certified Oncology Pharmacist (BCOP)<\/b><span style=\"font-weight: 400;\"> \u0647\u0648 \u0634\u0647\u0627\u062f\u0629 \u0645\u0646 <\/span><b>Board of Pharmacy Specialties (BPS)<\/b><span style=\"font-weight: 400;\"> \u0628\u062a\u062b\u0628\u062a \u0625\u0646\u0643 \u0635\u064a\u062f\u0644\u064a \u0645\u062a\u062e\u0635\u0635 \u0641\u064a <\/span><b>Oncology Pharmacy<\/b><span style=\"font-weight: 400;\">. \u0627\u0644\u0634\u0647\u0627\u062f\u0629 \u062f\u064a \u0628\u062a\u0642\u0648\u0644 \u0625\u0646\u0643 \u0642\u0627\u062f\u0631 \u062a\u0642\u062f\u0645 <\/span><b>Evidence-based, Patient-centered Medication Therapy Management<\/b><span style=\"font-weight: 400;\"> \u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0633\u0631\u0637\u0627\u0646.<\/span><\/p>\n<p><b>Oncology Pharmacy<\/b><span style=\"font-weight: 400;\"> \u0628\u064a\u062e\u062a\u0635 \u0641\u064a:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Treatment Assessment<\/b><span style=\"font-weight: 400;\"> \u2014 \u062a\u0642\u064a\u064a\u0645 \u0627\u0644\u062e\u0637\u0629 \u0627\u0644\u0639\u0644\u0627\u062c\u064a\u0629<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Monitoring for Adverse Drug Reactions<\/b><span style=\"font-weight: 400;\"> \u2014 \u0645\u062a\u0627\u0628\u0639\u0629 \u0627\u0644\u0622\u062b\u0627\u0631 \u0627\u0644\u062c\u0627\u0646\u0628\u064a\u0629<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Drug Interactions<\/b><span style=\"font-weight: 400;\"> \u2014 \u0627\u0644\u062a\u0641\u0627\u0639\u0644\u0627\u062a \u0627\u0644\u062f\u0648\u0627\u0626\u064a\u0629 \u0627\u0644\u0645\u0639\u0642\u062f\u0629<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Supportive Care<\/b><span style=\"font-weight: 400;\"> \u2014 \u0627\u0644\u0631\u0639\u0627\u064a\u0629 \u0627\u0644\u062f\u0627\u0639\u0645\u0629 (Antiemetics, Growth Factors, Pain Management)<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">\u062f\u0644\u0648\u0642\u062a\u064a \u0641\u064a \u0623\u0643\u062a\u0631 \u0645\u0646 <\/span><b>4,700 \u0635\u064a\u062f\u0644\u064a \u0645\u0639\u062a\u0645\u062f BCOP<\/b><span style=\"font-weight: 400;\"> \u062d\u0648\u0644 \u0627\u0644\u0639\u0627\u0644\u0645 \u2014 \u0648\u0627\u0644\u0639\u062f\u062f \u0628\u064a\u0632\u064a\u062f.<\/span><\/p>\n<h2><b>\u0645\u062d\u062a\u0648\u0649 \u0627\u0644\u0643\u0648\u0631\u0633 (Content Course)<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">\u0627\u0644\u0643\u0648\u0631\u0633 \u0628\u064a\u063a\u0637\u064a \u0643\u0644 \u062d\u0627\u062c\u0629 \u0645\u0646 \u062a\u0634\u062e\u064a\u0635 \u0627\u0644\u0633\u0631\u0637\u0627\u0646 \u0644\u062d\u062f \u0627\u0644\u0631\u0639\u0627\u064a\u0629 \u0637\u0648\u064a\u0644\u0629 \u0627\u0644\u0645\u062f\u0649:<\/span><\/p>\n<ol>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Gynecologic Malignancies<\/b><span style=\"font-weight: 400;\"> \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0646\u0633\u0627\u0621<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Prostate Cancer<\/b><span style=\"font-weight: 400;\"> \u2014 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0628\u0631\u0648\u0633\u062a\u0627\u062a\u0627<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Pediatric Malignancies and Supportive Care<\/b><span style=\"font-weight: 400;\"> \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0623\u0637\u0641\u0627\u0644<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Upper Gastrointestinal and Hepatocellular Carcinomas<\/b><span style=\"font-weight: 400;\"> \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0643\u0628\u062f \u0648\u0627\u0644\u0645\u0631\u064a\u0621<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Bladder, Renal Cell, and Testicular Cancers<\/b><span style=\"font-weight: 400;\"> \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0645\u0633\u0627\u0644\u0643 \u0627\u0644\u0628\u0648\u0644\u064a\u0629<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Melanoma and Non-Melanoma Skin Cancers<\/b><span style=\"font-weight: 400;\"> \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u062c\u0644\u062f<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Research Design, Statistics, and Evaluating Oncology Literature<\/b><span style=\"font-weight: 400;\"> \u2014 \u0627\u0644\u0625\u062d\u0635\u0627\u0621 \u0648\u0627\u0644\u0628\u062d\u062b<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Adult Acute Leukemias and Myelodysplastic Syndromes<\/b><span style=\"font-weight: 400;\"> \u2014 \u0627\u0644\u0644\u0648\u0643\u064a\u0645\u064a\u0627 \u0627\u0644\u062d\u0627\u062f\u0629<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Lymphomas<\/b><span style=\"font-weight: 400;\"> \u2014 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0644\u0645\u0641\u0627\u0648\u064a\u0629<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Chronic Leukemias<\/b><span style=\"font-weight: 400;\"> \u2014 \u0627\u0644\u0644\u0648\u0643\u064a\u0645\u064a\u0627 \u0627\u0644\u0645\u0632\u0645\u0646\u0629<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Hematopoietic Cell Transplantation<\/b><span style=\"font-weight: 400;\"> \u2014 \u0632\u0631\u0627\u0639\u0629 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062c\u0630\u0639\u064a\u0629<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Lung Cancer<\/b><span style=\"font-weight: 400;\"> \u2014 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Lower Gastrointestinal and Pancreatic Cancers<\/b><span style=\"font-weight: 400;\"> \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0642\u0648\u0644\u0648\u0646 \u0648\u0627\u0644\u0628\u0646\u0643\u0631\u064a\u0627\u0633<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Head, Neck, Adult CNS, and Thyroid Malignancies<\/b><span style=\"font-weight: 400;\"> \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0631\u0623\u0633 \u0648\u0627\u0644\u0631\u0642\u0628\u0629 \u0648\u0627\u0644\u062f\u0645\u0627\u063a<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Cancer-related Infectious Diseases<\/b><span style=\"font-weight: 400;\"> \u2014 \u0627\u0644\u0639\u062f\u0648\u0649 \u0627\u0644\u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0627\u0644\u0633\u0631\u0637\u0627\u0646<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Oncology Practice Management<\/b><span style=\"font-weight: 400;\"> \u2014 \u0625\u062f\u0627\u0631\u0629 \u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0623\u0648\u0631\u0627\u0645<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Multiple Myeloma<\/b><span style=\"font-weight: 400;\"> \u2014 \u0627\u0644\u0648\u0631\u0645 \u0627\u0644\u0646\u0642\u0648\u064a \u0627\u0644\u0645\u062a\u0639\u062f\u062f<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Adult Sarcomas<\/b><span style=\"font-weight: 400;\"> \u2014 \u0627\u0644\u0633\u0627\u0631\u0643\u0648\u0645\u0627<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Pharmacogenomics in Oncology<\/b><span style=\"font-weight: 400;\"> \u2014 \u0627\u0644\u0635\u064a\u062f\u0644\u0629 \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629 \u0641\u064a \u0627\u0644\u0623\u0648\u0631\u0627\u0645<\/span><\/li>\n<\/ol>\n<p><span style=\"font-weight: 400;\">\u064a\u0639\u0646\u064a \u0625\u0646\u062a \u0628\u062a\u062f\u0631\u0633 <\/span><b>\u0643\u0644 \u0646\u0648\u0639 \u0633\u0631\u0637\u0627\u0646<\/b><span style=\"font-weight: 400;\"> \u2014 \u0645\u0646 \u0627\u0644\u062c\u0644\u062f \u0644\u062d\u062f \u0627\u0644\u062f\u0645\u0627\u063a\u060c \u0648\u0645\u0646 \u0627\u0644\u0643\u064a\u0645\u0627\u0648\u064a \u0644\u062d\u062f \u0627\u0644\u0645\u0646\u0627\u0639\u064a \u0648\u0627\u0644\u062c\u064a\u0646\u064a.<\/span><\/p>\n<h2><b>\u0627\u0644\u0627\u0645\u062a\u062d\u0627\u0646 \u2014 \u0625\u064a\u0647 \u0627\u0644\u0644\u064a \u0628\u064a\u062c\u064a\u061f (BCOP Examination Specifications)<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">\u062d\u0633\u0628 <\/span><b>Role Delineation Study<\/b><span style=\"font-weight: 400;\"> (2022):<\/span><\/p>\n<p>&nbsp;<\/p>\n<table>\n<tbody>\n<tr>\n<td><b>\u0627\u0644\u0645\u062c\u0627\u0644<\/b><\/td>\n<td><b>\u0627\u0644\u0646\u0633\u0628\u0629<\/b><\/td>\n<td><b>\u0639\u062f\u062f \u0627\u0644\u0623\u0633\u0626\u0644\u0629<\/b><\/td>\n<td><b>\u064a\u0639\u0646\u064a \u0625\u064a\u0647\u061f<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>1. Oncology Diagnosis and Testing<\/b><\/td>\n<td><b>22.1%<\/b><\/td>\n<td><span style=\"font-weight: 400;\">28<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u062a\u0634\u062e\u064a\u0635 \u0627\u0644\u0633\u0631\u0637\u0627\u0646\u060c \u0627\u0644\u062c\u064a\u0646\u0627\u062a\u060c Biomarkers<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>1A. Oncology Diagnosis<\/b><\/td>\n<td><span style=\"font-weight: 400;\">9.0%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">11<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Etiology, Pathophysiology, Types of Cancer<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>1B. Oncology Testing<\/b><\/td>\n<td><span style=\"font-weight: 400;\">8.5%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">11<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Genomics, NGS, Biomarker Testing (PDL1, TMB)<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>1C. Cancer Detection and Prevention<\/b><\/td>\n<td><span style=\"font-weight: 400;\">4.6%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">6<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Screening, Prevention<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>2. Therapeutics and Patient Management<\/b><\/td>\n<td><b>49.2%<\/b><\/td>\n<td><span style=\"font-weight: 400;\">61<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0625\u062f\u0627\u0631\u062a\u0647<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>2A. Treatment Planning<\/b><\/td>\n<td><span style=\"font-weight: 400;\">15.8%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">20<\/span><\/td>\n<td><span style=\"font-weight: 400;\">NCCN Guidelines, Palliative Care, Survivorship<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>2B. Therapeutic Implementation<\/b><\/td>\n<td><span style=\"font-weight: 400;\">16.2%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">20<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Pharmacotherapy, Drug Administration, Education<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>2C. Cancer Outcomes and Treatment Monitoring<\/b><\/td>\n<td><span style=\"font-weight: 400;\">17.2%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">21<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Toxicity Management, Oncologic Emergencies, Drug Resistance<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>3. Professional Practice<\/b><\/td>\n<td><b>28.7%<\/b><\/td>\n<td><span style=\"font-weight: 400;\">36<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0645\u0647\u0646\u064a\u0629<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>3A. Clinical Trials and Research<\/b><\/td>\n<td><span style=\"font-weight: 400;\">14.3%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">18<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Research Methods, IRB, Drug Approval Process<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>3B. Practice Management<\/b><\/td>\n<td><span style=\"font-weight: 400;\">14.4%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">18<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Quality Management, USP&lt;800&gt;, REMS, Biosimilars<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><b>\u062a\u0641\u0627\u0635\u064a\u0644 \u0627\u0644\u0627\u0645\u062a\u062d\u0627\u0646:<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>150 \u0633\u0624\u0627\u0644<\/b><span style=\"font-weight: 400;\"> (125 scored + 25 pretest)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>3 \u0633\u0627\u0639\u0627\u062a \u0648 45 \u062f\u0642\u064a\u0642\u0629<\/b><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Forward Only Format \u2014 \u0645\u0634 \u0628\u062a\u0631\u062c\u0639 \u0644\u0644\u0633\u0624\u0627\u0644 \u0627\u0644\u0633\u0627\u0628\u0642<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Scale:<\/b><span style=\"font-weight: 400;\"> 200-800\u060c \u0648\u0627\u0644\u0640 Passing Score \u0647\u0648 <\/span><b>500<\/b><\/li>\n<\/ul>\n<h2><b>\u0634\u0631\u0648\u0637 \u0627\u0644\u0623\u0647\u0644\u064a\u0629 (Eligibility)<\/b><\/h2>\n<ol>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>\u062e\u0631\u064a\u062c \u0645\u0646<\/b><span style=\"font-weight: 400;\"> \u0643\u0644\u064a\u0629 \u0635\u064a\u062f\u0644\u0629 \u0645\u0639\u062a\u0645\u062f\u0629<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>\u062a\u0631\u062e\u064a\u0635<\/b><span style=\"font-weight: 400;\"> \u0645\u0632\u0627\u0648\u0644\u0629 \u0645\u0647\u0646\u0629 \u0633\u0627\u0631\u064a<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>\u0648\u0627\u062d\u062f \u0645\u0646 \u0627\u0644\u062a\u0627\u0644\u064a \u062e\u0644\u0627\u0644 \u0622\u062e\u0631 7 \u0633\u0646\u064a\u0646:<\/b>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><b>4 \u0633\u0646\u064a\u0646<\/b><span style=\"font-weight: 400;\"> \u062e\u0628\u0631\u0629 \u0641\u064a Oncology Pharmacy (50% \u0645\u0646 \u0627\u0644\u0648\u0642\u062a \u0639\u0644\u0649 \u0627\u0644\u0623\u0642\u0644)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><b>PGY1 Residency<\/b><span style=\"font-weight: 400;\"> + <\/span><b>1 \u0633\u0646\u0629<\/b><span style=\"font-weight: 400;\"> \u062e\u0628\u0631\u0629 \u0641\u064a Oncology (50% \u0639\u0644\u0649 \u0627\u0644\u0623\u0642\u0644)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><b>PGY2 Residency<\/b><span style=\"font-weight: 400;\"> \u0641\u064a Oncology Pharmacy<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<h2><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-6420 aligncenter\" src=\"https:\/\/team4bps.com\/wp-content\/uploads\/2026\/06\/\u0627\u0644\u0628\u0648\u0631\u062f-\u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a-\u0641\u064a-\u0635\u064a\u062f\u0644\u0629-\u0627\u0644\u0623\u0648\u0631\u0627\u0645-300x136.webp\" alt=\"\" width=\"1246\" height=\"565\" srcset=\"https:\/\/team4bps.com\/wp-content\/uploads\/2026\/06\/\u0627\u0644\u0628\u0648\u0631\u062f-\u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a-\u0641\u064a-\u0635\u064a\u062f\u0644\u0629-\u0627\u0644\u0623\u0648\u0631\u0627\u0645-300x136.webp 300w, https:\/\/team4bps.com\/wp-content\/uploads\/2026\/06\/\u0627\u0644\u0628\u0648\u0631\u062f-\u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a-\u0641\u064a-\u0635\u064a\u062f\u0644\u0629-\u0627\u0644\u0623\u0648\u0631\u0627\u0645-1024x464.webp 1024w, https:\/\/team4bps.com\/wp-content\/uploads\/2026\/06\/\u0627\u0644\u0628\u0648\u0631\u062f-\u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a-\u0641\u064a-\u0635\u064a\u062f\u0644\u0629-\u0627\u0644\u0623\u0648\u0631\u0627\u0645-768x348.webp 768w, https:\/\/team4bps.com\/wp-content\/uploads\/2026\/06\/\u0627\u0644\u0628\u0648\u0631\u062f-\u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a-\u0641\u064a-\u0635\u064a\u062f\u0644\u0629-\u0627\u0644\u0623\u0648\u0631\u0627\u0645-1536x696.webp 1536w, https:\/\/team4bps.com\/wp-content\/uploads\/2026\/06\/\u0627\u0644\u0628\u0648\u0631\u062f-\u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a-\u0641\u064a-\u0635\u064a\u062f\u0644\u0629-\u0627\u0644\u0623\u0648\u0631\u0627\u0645-18x8.webp 18w, https:\/\/team4bps.com\/wp-content\/uploads\/2026\/06\/\u0627\u0644\u0628\u0648\u0631\u062f-\u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a-\u0641\u064a-\u0635\u064a\u062f\u0644\u0629-\u0627\u0644\u0623\u0648\u0631\u0627\u0645.webp 1700w\" sizes=\"(max-width: 1246px) 100vw, 1246px\" \/><\/h2>\n<p>&nbsp;<\/p>\n<h2><b>\u0627\u0644\u062e\u0644\u0627\u0635\u0629<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">\u0627\u0644\u0628\u0648\u0631\u062f \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a (BCOP) \u0645\u0634 \u0628\u0633 \u0634\u0647\u0627\u062f\u0629\u060c \u062f\u0647 <\/span><b>\u0627\u0639\u062a\u0631\u0627\u0641 \u062f\u0648\u0644\u064a<\/b><span style=\"font-weight: 400;\"> \u0628\u0625\u0646\u0643 \u0642\u0627\u062f\u0631 \u062a\u062a\u0639\u0627\u0645\u0644 \u0645\u0639 \u0623\u0635\u0639\u0628 \u0627\u0644\u062d\u0627\u0644\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0641\u064a \u0645\u062c\u0627\u0644 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 .<\/span><\/p>\n<p>&nbsp;<\/p>\n<h3><b>\u0644\u0644\u062d\u062c\u0632 \u0648\u0627\u0644\u0627\u0633\u062a\u0641\u0633\u0627\u0631 \u0639\u0646 \u0643\u0648\u0631\u0633 BCOP<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">\ud83d\udcf1 <\/span><b>\u0648\u0627\u062a\u0633\u0627\u0628: 00201064200742<\/b><\/p>\n<p><b>\u0623\u0643\u0627\u062f\u064a\u0645\u064a\u0629 \u0627\u0644\u0641\u0631\u064a\u0642<\/b><span style=\"font-weight: 400;\"> \u2014 <\/span><b>Your Way to the American Board of Pharmacy Specialties<\/b><span style=\"font-weight: 400;\"> \ud83c\udf93<\/span><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>\u0627\u0644\u0641\u062a\u0631\u0629 \u0627\u0644\u0623\u062e\u064a\u0631\u0629 \u0641\u064a\u0647 \u062a\u0632\u0627\u064a\u062f \u0643\u0628\u064a\u0631 \u062c\u062f\u0627\u064b \u0641\u064a \u0637\u0644\u0628\u0627\u062a \u062a\u0648\u0638\u064a\u0641 \u0627\u0644\u0635\u064a\u0627\u062f\u0644\u0629 \u0627\u0644\u062d\u0627\u0635\u0644\u064a\u0646 \u0639\u0644\u0649 \u0627\u0644\u0628\u0648\u0631\u062f \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a \u0641\u064a \u062a\u062e\u0635\u0635 \u0627\u0644\u0623\u0648\u0631\u0627\u0645\u061f\u00a0 \u0627\u0644\u0639\u062f\u062f \u0627\u0644\u0645\u0637\u0644\u0648\u0628 \u0623\u0643\u0628\u0631 \u0645\u0646 \u0627\u0644\u0645\u062a\u0627\u062d \u2014 \u0633\u0648\u0627\u0621 \u0641\u064a \u0645\u0635\u0631 \u0623\u0648 \u0627\u0644\u0648\u0637\u0646 \u0627\u0644\u0639\u0631\u0628\u064a. \u0644\u0623\u0646 \u0623\u0639\u062f\u0627\u062f \u0627\u0644\u0645\u0633\u062a\u0634\u0641\u064a\u0627\u062a \u0627\u0644\u062d\u0643\u0648\u0645\u064a\u0629 \u0648\u0627\u0644\u0645\u0631\u0627\u0643\u0632 \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0639\u0644\u0627\u062c \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0628\u064a\u0632\u064a\u062f \u0639\u062f\u062f\u0647\u0627 \u0643\u0644 \u0633\u0646\u0629. \u0627\u0644\u062d\u0627\u062c\u0629 \u0627\u0644\u0645\u0644\u062d\u0629 \u062f\u0644\u0648\u0642\u062a\u064a \u0635\u064a\u062f\u0644\u064a \u0625\u0643\u0644\u064a\u0646\u064a\u0643\u064a \u0645\u062a\u062e\u0635\u0635 \u0642\u0627\u062f\u0631 \u0639\u0644\u0649: \u062a\u0642\u064a\u064a\u0645 \u0627\u0644\u062d\u0627\u0644\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u0645\u0631\u064a\u0636 \u062d\u0633\u0627\u0628 \u0627\u0644\u062c\u0631\u0639\u0627\u062a \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (Chemotherapy Dosing) \u0645\u062a\u0627\u0628\u0639\u0629 \u0627\u0644\u062a\u0641\u0627\u0639\u0644\u0627\u062a \u0627\u0644\u062f\u0648\u0627\u0626\u064a\u0629 (Drug Interactions) \u0645\u0631\u0627\u0642\u0628\u0629 \u0627\u0644\u062a\u0623\u062b\u064a\u0631\u0627\u062a \u0627\u0644\u062d\u064a\u0648\u064a\u0629 \u0639\u0644\u0649 \u062c\u0645\u064a\u0639 \u0623\u0639\u0636\u0627\u0621 \u0627\u0644\u062c\u0633\u0645 (Organ Toxicity) \u0625\u064a\u0647 \u0647\u0648 \u0627\u0644\u0628\u0648\u0631\u062f \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a \u0641\u064a \u0635\u064a\u062f\u0644\u0629 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 (BCOP)\u061f Board-Certified Oncology Pharmacist (BCOP) \u0647\u0648 \u0634\u0647\u0627\u062f\u0629 \u0645\u0646 Board of Pharmacy Specialties (BPS) \u0628\u062a\u062b\u0628\u062a \u0625\u0646\u0643 \u0635\u064a\u062f\u0644\u064a \u0645\u062a\u062e\u0635\u0635 \u0641\u064a Oncology Pharmacy. \u0627\u0644\u0634\u0647\u0627\u062f\u0629 \u062f\u064a \u0628\u062a\u0642\u0648\u0644 \u0625\u0646\u0643 \u0642\u0627\u062f\u0631 \u062a\u0642\u062f\u0645 Evidence-based, Patient-centered Medication Therapy Management \u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0633\u0631\u0637\u0627\u0646. Oncology Pharmacy \u0628\u064a\u062e\u062a\u0635 \u0641\u064a: Treatment Assessment \u2014 \u062a\u0642\u064a\u064a\u0645 \u0627\u0644\u062e\u0637\u0629 \u0627\u0644\u0639\u0644\u0627\u062c\u064a\u0629 Monitoring for Adverse Drug Reactions \u2014 \u0645\u062a\u0627\u0628\u0639\u0629 \u0627\u0644\u0622\u062b\u0627\u0631 \u0627\u0644\u062c\u0627\u0646\u0628\u064a\u0629 Drug Interactions \u2014 \u0627\u0644\u062a\u0641\u0627\u0639\u0644\u0627\u062a \u0627\u0644\u062f\u0648\u0627\u0626\u064a\u0629 \u0627\u0644\u0645\u0639\u0642\u062f\u0629 Supportive Care \u2014 \u0627\u0644\u0631\u0639\u0627\u064a\u0629 \u0627\u0644\u062f\u0627\u0639\u0645\u0629 (Antiemetics, Growth Factors, Pain Management) \u062f\u0644\u0648\u0642\u062a\u064a \u0641\u064a \u0623\u0643\u062a\u0631 \u0645\u0646 4,700 \u0635\u064a\u062f\u0644\u064a \u0645\u0639\u062a\u0645\u062f BCOP \u062d\u0648\u0644 \u0627\u0644\u0639\u0627\u0644\u0645 \u2014 \u0648\u0627\u0644\u0639\u062f\u062f \u0628\u064a\u0632\u064a\u062f. \u0645\u062d\u062a\u0648\u0649 \u0627\u0644\u0643\u0648\u0631\u0633 (Content Course) \u0627\u0644\u0643\u0648\u0631\u0633 \u0628\u064a\u063a\u0637\u064a \u0643\u0644 \u062d\u0627\u062c\u0629 \u0645\u0646 \u062a\u0634\u062e\u064a\u0635 \u0627\u0644\u0633\u0631\u0637\u0627\u0646 \u0644\u062d\u062f \u0627\u0644\u0631\u0639\u0627\u064a\u0629 \u0637\u0648\u064a\u0644\u0629 \u0627\u0644\u0645\u062f\u0649: Gynecologic Malignancies \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0646\u0633\u0627\u0621 Prostate Cancer \u2014 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0628\u0631\u0648\u0633\u062a\u0627\u062a\u0627 Pediatric Malignancies and Supportive Care \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0623\u0637\u0641\u0627\u0644 Upper Gastrointestinal and Hepatocellular Carcinomas \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0643\u0628\u062f \u0648\u0627\u0644\u0645\u0631\u064a\u0621 Bladder, Renal Cell, and Testicular Cancers \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0645\u0633\u0627\u0644\u0643 \u0627\u0644\u0628\u0648\u0644\u064a\u0629 Melanoma and Non-Melanoma Skin Cancers \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u062c\u0644\u062f Research Design, Statistics, and Evaluating Oncology Literature \u2014 \u0627\u0644\u0625\u062d\u0635\u0627\u0621 \u0648\u0627\u0644\u0628\u062d\u062b Adult Acute Leukemias and Myelodysplastic Syndromes \u2014 \u0627\u0644\u0644\u0648\u0643\u064a\u0645\u064a\u0627 \u0627\u0644\u062d\u0627\u062f\u0629 Lymphomas \u2014 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0644\u0645\u0641\u0627\u0648\u064a\u0629 Chronic Leukemias \u2014 \u0627\u0644\u0644\u0648\u0643\u064a\u0645\u064a\u0627 \u0627\u0644\u0645\u0632\u0645\u0646\u0629 Hematopoietic Cell Transplantation \u2014 \u0632\u0631\u0627\u0639\u0629 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u062c\u0630\u0639\u064a\u0629 Lung Cancer \u2014 \u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0631\u0626\u0629 Lower Gastrointestinal and Pancreatic Cancers \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0642\u0648\u0644\u0648\u0646 \u0648\u0627\u0644\u0628\u0646\u0643\u0631\u064a\u0627\u0633 Head, Neck, Adult CNS, and Thyroid Malignancies \u2014 \u0623\u0648\u0631\u0627\u0645 \u0627\u0644\u0631\u0623\u0633 \u0648\u0627\u0644\u0631\u0642\u0628\u0629 \u0648\u0627\u0644\u062f\u0645\u0627\u063a Cancer-related Infectious Diseases \u2014 \u0627\u0644\u0639\u062f\u0648\u0649 \u0627\u0644\u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0627\u0644\u0633\u0631\u0637\u0627\u0646 Oncology Practice Management \u2014 \u0625\u062f\u0627\u0631\u0629 \u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 Multiple Myeloma \u2014 \u0627\u0644\u0648\u0631\u0645 \u0627\u0644\u0646\u0642\u0648\u064a \u0627\u0644\u0645\u062a\u0639\u062f\u062f Adult Sarcomas \u2014 \u0627\u0644\u0633\u0627\u0631\u0643\u0648\u0645\u0627 Pharmacogenomics in Oncology \u2014 \u0627\u0644\u0635\u064a\u062f\u0644\u0629 \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629 \u0641\u064a \u0627\u0644\u0623\u0648\u0631\u0627\u0645 \u064a\u0639\u0646\u064a \u0625\u0646\u062a \u0628\u062a\u062f\u0631\u0633 \u0643\u0644 \u0646\u0648\u0639 \u0633\u0631\u0637\u0627\u0646 \u2014 \u0645\u0646 \u0627\u0644\u062c\u0644\u062f \u0644\u062d\u062f \u0627\u0644\u062f\u0645\u0627\u063a\u060c \u0648\u0645\u0646 \u0627\u0644\u0643\u064a\u0645\u0627\u0648\u064a \u0644\u062d\u062f \u0627\u0644\u0645\u0646\u0627\u0639\u064a \u0648\u0627\u0644\u062c\u064a\u0646\u064a. \u0627\u0644\u0627\u0645\u062a\u062d\u0627\u0646 \u2014 \u0625\u064a\u0647 \u0627\u0644\u0644\u064a \u0628\u064a\u062c\u064a\u061f (BCOP Examination Specifications) \u062d\u0633\u0628 Role Delineation Study (2022): &nbsp; \u0627\u0644\u0645\u062c\u0627\u0644 \u0627\u0644\u0646\u0633\u0628\u0629 \u0639\u062f\u062f \u0627\u0644\u0623\u0633\u0626\u0644\u0629 \u064a\u0639\u0646\u064a \u0625\u064a\u0647\u061f 1. Oncology Diagnosis and Testing 22.1% 28 \u062a\u0634\u062e\u064a\u0635 \u0627\u0644\u0633\u0631\u0637\u0627\u0646\u060c \u0627\u0644\u062c\u064a\u0646\u0627\u062a\u060c Biomarkers 1A. Oncology Diagnosis 9.0% 11 Etiology, Pathophysiology, Types of Cancer 1B. Oncology Testing 8.5% 11 Genomics, NGS, Biomarker Testing (PDL1, TMB) 1C. Cancer Detection and Prevention 4.6% 6 Screening, Prevention 2. Therapeutics and Patient Management 49.2% 61 \u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0625\u062f\u0627\u0631\u062a\u0647 2A. Treatment Planning 15.8% 20 NCCN Guidelines, Palliative Care, Survivorship 2B. Therapeutic Implementation 16.2% 20 Pharmacotherapy, Drug Administration, Education 2C. Cancer Outcomes and Treatment Monitoring 17.2% 21 Toxicity Management, Oncologic Emergencies, Drug Resistance 3. Professional Practice 28.7% 36 \u0627\u0644\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0645\u0647\u0646\u064a\u0629 3A. Clinical Trials and Research 14.3% 18 Research Methods, IRB, Drug Approval Process 3B. Practice Management 14.4% 18 Quality Management, USP&lt;800&gt;, REMS, Biosimilars \u062a\u0641\u0627\u0635\u064a\u0644 \u0627\u0644\u0627\u0645\u062a\u062d\u0627\u0646: 150 \u0633\u0624\u0627\u0644 (125 scored + 25 pretest) 3 \u0633\u0627\u0639\u0627\u062a \u0648 45 \u062f\u0642\u064a\u0642\u0629 Forward Only Format \u2014 \u0645\u0634 \u0628\u062a\u0631\u062c\u0639 \u0644\u0644\u0633\u0624\u0627\u0644 \u0627\u0644\u0633\u0627\u0628\u0642 Scale: 200-800\u060c \u0648\u0627\u0644\u0640 Passing Score \u0647\u0648 500 \u0634\u0631\u0648\u0637 \u0627\u0644\u0623\u0647\u0644\u064a\u0629 (Eligibility) \u062e\u0631\u064a\u062c \u0645\u0646 \u0643\u0644\u064a\u0629 \u0635\u064a\u062f\u0644\u0629 \u0645\u0639\u062a\u0645\u062f\u0629 \u062a\u0631\u062e\u064a\u0635 \u0645\u0632\u0627\u0648\u0644\u0629 \u0645\u0647\u0646\u0629 \u0633\u0627\u0631\u064a \u0648\u0627\u062d\u062f \u0645\u0646 \u0627\u0644\u062a\u0627\u0644\u064a \u062e\u0644\u0627\u0644 \u0622\u062e\u0631 7 \u0633\u0646\u064a\u0646: 4 \u0633\u0646\u064a\u0646 \u062e\u0628\u0631\u0629 \u0641\u064a Oncology Pharmacy (50% \u0645\u0646 \u0627\u0644\u0648\u0642\u062a \u0639\u0644\u0649 \u0627\u0644\u0623\u0642\u0644) PGY1 Residency + 1 \u0633\u0646\u0629 \u062e\u0628\u0631\u0629 \u0641\u064a Oncology (50% \u0639\u0644\u0649 \u0627\u0644\u0623\u0642\u0644) PGY2 Residency \u0641\u064a Oncology Pharmacy &nbsp; \u0627\u0644\u062e\u0644\u0627\u0635\u0629 \u0627\u0644\u0628\u0648\u0631\u062f \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a (BCOP) \u0645\u0634 \u0628\u0633 \u0634\u0647\u0627\u062f\u0629\u060c \u062f\u0647 \u0627\u0639\u062a\u0631\u0627\u0641 \u062f\u0648\u0644\u064a \u0628\u0625\u0646\u0643 \u0642\u0627\u062f\u0631 \u062a\u062a\u0639\u0627\u0645\u0644 \u0645\u0639 \u0623\u0635\u0639\u0628 \u0627\u0644\u062d\u0627\u0644\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0641\u064a \u0645\u062c\u0627\u0644 \u0627\u0644\u0623\u0648\u0631\u0627\u0645 . &nbsp; \u0644\u0644\u062d\u062c\u0632 \u0648\u0627\u0644\u0627\u0633\u062a\u0641\u0633\u0627\u0631 \u0639\u0646 \u0643\u0648\u0631\u0633 BCOP \ud83d\udcf1 \u0648\u0627\u062a\u0633\u0627\u0628: 00201064200742 TEAM Academy \u2014 Your Way to the American Board of Pharmacy Specialties \ud83c\udf93 &nbsp;<\/p>","protected":false},"author":2,"featured_media":6421,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6419","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-1"],"acf":[],"wps_subtitle":"","_links":{"self":[{"href":"https:\/\/team4bps.com\/ar\/wp-json\/wp\/v2\/posts\/6419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/team4bps.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/team4bps.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/team4bps.com\/ar\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/team4bps.com\/ar\/wp-json\/wp\/v2\/comments?post=6419"}],"version-history":[{"count":2,"href":"https:\/\/team4bps.com\/ar\/wp-json\/wp\/v2\/posts\/6419\/revisions"}],"predecessor-version":[{"id":6423,"href":"https:\/\/team4bps.com\/ar\/wp-json\/wp\/v2\/posts\/6419\/revisions\/6423"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/team4bps.com\/ar\/wp-json\/wp\/v2\/media\/6421"}],"wp:attachment":[{"href":"https:\/\/team4bps.com\/ar\/wp-json\/wp\/v2\/media?parent=6419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/team4bps.com\/ar\/wp-json\/wp\/v2\/categories?post=6419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/team4bps.com\/ar\/wp-json\/wp\/v2\/tags?post=6419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}